Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Transplant lifesaver linked to cancer risk: study investigates

NCT ID NCT02121730

Knowledge-focused Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 2,500 kidney transplant patients to find out why some develop cancer. The main focus was on the immunosuppressive drugs that prevent organ rejection, which can also raise cancer risk. Researchers tracked patients from four regions in France over 10 years to identify key risk factors for skin and solid tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,500 people

The number who actually took part.

Started

Nov 2014

Finished

Aug 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who had undergone renal transplantation for 10 years in the French interregion Northwest (Normandy, Picardy and Nord-Pas de Calais).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All adult renal transplant patients in the 4 centers of interregion North - West * Patients transplanted during the period from 1 January 2002 and 31 December 2011 * Patients recipients of first, second or third renal transplantation * Patients transplant recipients from a living or deceased donor whatever the immunological risk * Eligible patients will be included after being informed by their doctor and after accepting their data to be processed in the framework of this study * Patient with a health insurance coverage Exclusion Criteria: * Patients transplanted as child * Patients transplanted before 1 January 2002 * Patients followed in the interregion but transplanted in another center * Patients recipients of a double transplant (two kidneys or kidney plus other organ) * Patients that do not accept their medical data to be included in the database

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer of kidney are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

end stage renal failure kidney cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer of kidney

Contacts and locations

Locations

  • CHU Amiens

    Amiens, 80000, France

  • CHU CAEN

    Caen, 14000, France

  • Chru Lille

    Lille, 59000, France

  • Chu Rouen

    Rouen, 76000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.